Orexigen's Contrave successful in Phase III obesity trial
This article was originally published in Scrip
Executive Summary
Orexigen Therapeutics' lead candidate Contrave (naltrexone 32mg sustained- release (SR)/ bupropion 360mg SR), a potential obesity treatment, met its primary endpoints in the first of four Phase III trials, showing a reduction in body weight, improvements in markers of cardiovascular risk and reductions in selected food craving measures.